Belen Garijo, President & CEO Merck Serono, addressed the recent BIO CEO & Investor Conference in NYC.
Merck Serono is an $8 billion (2013 revenue) specialty PHARMA company, that sees itself as a leader in personalized medicine. The German company is trying to position itself in the Immuno-oncology sector (estimated at $30 billion). “We’re all looking for the same thing — late stage oncology (compounds),” said Ms. Garijo.
Photograph: Stephen Wise
LOTUS EDITIONS 